Keeler Thomas Management LLC Purchases Shares of 99,357 Pfizer Inc. $PFE

Key Points

• Keeler Thomas Management LLC recently acquired 99,357 shares of Pfizer Inc., valued at approximately $2.41 million, making it the firm's 20th largest investment.
• Pfizer's quarterly earnings exceeded expectations, reporting $0.78 earnings per share and a revenue of $14.65 billion, marking a 10.3% increase year-over-year.
• The company declared a quarterly dividend of $0.43 per share, scheduled for payment on December 1st, representing a 6.9% dividend yield.

Keeler Thomas Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 99,357 shares of the biopharmaceutical company's stock, valued at approximately $2,408,000. Pfizer accounts for about 1.0% of Keeler Thomas Management LLC's investment portfolio, making the stock its 20th largest position.

A number of other hedge funds have also recently bought and sold shares of PFE. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Pfizer by 69.0% in the 1st quarter. GAMMA Investing LLC now owns 63,131 shares of the biopharmaceutical company's stock valued at $1,600,000 after buying an additional 25,785 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Finally, Perigon Wealth Management LLC raised its stake in shares of Pfizer by 5.2% in the 1st quarter. Perigon Wealth Management LLC now owns 118,361 shares of the biopharmaceutical company's stock valued at $2,999,000 after buying an additional 5,857 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research report on Friday, October 10th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, UBS Group reiterated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $28.13.

Pfizer Trading Up 0.5%

PFE opened at $24.79 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $140.92 billion, a PE ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17. The firm has a 50-day moving average price of $24.87 and a two-hundred day moving average price of $24.17.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.